The diabetes drug metformin is linked to improved ovarian cancer survival, researchers at the Mayo Clinic in Rochester, Minn., say. Sanjeev Kumar of the Mayo Clinic College of Medicine and colleagues analyzed the records of 239 women who had ovarian cancer and compared them to those who had taken metformin with those who had not. The study, published online in the journal Cancer, found 67 percent of those who took the drug had not died from ovarian cancer within five years, compared to 47 percent of those who didn't take the drug. Even after adjusting for stage, treatments received and the subtype of ovarian cancer, the data showed that ovarian cancer patients taking metformin had more than double the survival than those who didn't take the medication, Kumar said. Still, researchers need to do a lot more study before they can say for sure that metformin is safe and effective for this use, because is not currently available as an ovarian cancer treatment, the study said. All the women in the study who took the drug were already taking it to treat their diabetes, Kumar explained.
GMT 10:31 2018 Tuesday ,13 November
Russian police uproot 70 underground drug labs in past six monthsGMT 16:32 2018 Tuesday ,06 November
Rwanda aims to achieve universal access to clean water by 2024GMT 16:57 2018 Sunday ,04 November
Palestinian women witness higher cure rate of breast cancerGMT 13:11 2018 Tuesday ,30 October
Emergency surgery saves life of touristGMT 10:44 2018 Tuesday ,23 October
Scientists find microplastics in human stool for first timeGMT 09:18 2018 Tuesday ,23 October
US judge upholds Monsanto weedkiller cancer verdict, reduces payoutGMT 14:22 2018 Friday ,19 October
Birth spacing ‘improving health of Omani women’GMT 15:40 2018 Monday ,15 October
Pakistani president launches nationwide anti-measles driveMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor